source
- FDA to appoint permanent heads of CBER and CDER alongside new commissionerThe FDA is preparing to announce a series of senior leadership changes concurrent with the appointment of a new commissioner. Among the planned announcements are permanent appointments for the hea…
- Agios halts development of next‑generation sickle‑cell drug tebapivat after disappointing mid‑stage trialAgios Therapeutics announced it will discontinue development of tebapivat, a next‑generation therapy for sickle cell disease, after the drug failed to demonstrate sufficient efficacy in a Phase 2 t…